Cardiomyocytes undergoing apoptosis have been found in a variety of pathological conditions, such as dilated cardiomyopathy, ischaemia/reperfusion injury, myocardial infarction and end-stage heart failure
.
Studies have showed that death-receptor-induced apoptotic responses are involved in the pathogenesis of cardiac diseases [3] .
The death-receptor-mediated apoptotic pathway is triggered by the binding of death-receptor ligands, such as tumour necrosis factor-␣ (TNF-␣), to membrane-bound death receptors, such as TNF-␣ receptor 1 (TNF-R1). The interaction subsequently leads to activation of caspase-8. Activated caspase-8 then cleaves Bid into t-Bid, which promotes instability of the outer mitochondrial membrane, resulting in the release of cytochrome c into the cytosol.
Once in the cytosol, cytochrome c activates caspase-9, which then further cleaves and activates caspase-3, causing the induction of apoptosis [4] . [5] . Many studies have suggested that LPS contributes to cardiovascular collapse. Administration of LPS has been demonstrated to mediate vascular inflammation in atherosclerosis [6] . Furthermore, studies have demonstrated that LPS directly decreases contractility [7] and dramatically induces TNF-␣ expression [8] [9] .
Lipopolisaccharide (LPS) from gram-negative bacteria stimulates an inflammatory response by inducing the up-regulation and release of cytokines

in cardiomyocytes through binding to its specific toll-like receptor-4 (TLR-4). Clinical studies have shown that severe and potentially fatal hypotension and cardiac contractile dysfunction are common symptoms in patients with sepsis
It is well established today that the prevalence of cardiovascular diseases is lower in pre-menopausal women than in agematched men [9] and that estrogen-replacement therapy contributes to a low incidence of heart disease after menopause [10] . Clinical studies of patients with sepsis have revealed that the mortality rate and the levels of TNF-␣ are lower in women than in men [11] . In addition, it has been shown that estrogen replacement reduces both myocardial infarct size and ventricular arrhythmias induced by ischaemia/reperfusion in both female and male rabbits [12] . Furthermore, 17␤-estradiol (E2) has been shown to reduce pathological cardiac hypertrophy and heart failure by up-regulating the PI3K-Akt signalling pathway and by suppressing the calcineurin-NFAT3 signalling pathway in female rats [13] .
In the present study, we investigated whether E2 and/or ER␣ inhibits LPS-induced apoptosis in Doxinducible Tet-On H9c2 myocardial cells and primary cardiomyocytes that overexpress ER␣. We then identified the precise molecular and cellular mechanisms behind the cardioprotective effects of E2 and ER␣. Our findings suggest that E2 and ER␣ can significantly protect myocardial H9c2 cells and cardiomyocytes from LPS-induced apoptosis. Moreover, we found that the PI3K-Akt pathway is required for E2 and ER␣ to block LPS-up-regulated JNK1/2 activation, IB degradation, NFB activation as well as to block LPS-induced increases in proapoptotic proteins, thereby inhibiting LPS-induced myocardial cell damage.
Materials and methods
Cells, antibodies, reagents and enzymes
Heart-derived H9c2 myocardial cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 100 g/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine, 1 (Fig. 1B) (Fig. 2E ). (Fig. 3A) . (Fig. 3B) (Fig. 3D ).
Immunoblotting and immunoprecipitation
Results
LPS induces Tet-On/ER␣ H9c2 myocardial cell apoptosis
To identify the cytotoxic effect induced by LPS in myocardial cells, the inducible Tet-On/ER␣ H9c2 myocardial cells established in this study were incubated with LPS, a specific TLR4 agonist, and subjected to TUNEL analysis. After incubation with various concentrations of LPS (0-1000 ng/ml) for 24 hrs, we observed a significant dose-dependent reduction in cell viability. Few positively stained cells were noted in control cultures; however, in cultures treated with LPS (50-1000 ng/ml) for 24 hrs, there was a dose-dependent increase in the number of cells undergoing apoptosis (Fig. 1A). Immunoblotting assay was used to determine the expression levels of pro-apoptotic proteins, including TNF-␣, active caspase-8, truncated Bid (tBid), released cytochrome c, active caspase-9 and active caspase-3 in Tet-On/ER␣ H9c2 myocardial cells after LPS (0-5 g/ml) treatment. The results demonstrated that LPS dramatically induced the expression and activation of these pro-apoptotic proteins
E 2 , BSA-E 2 and ER␣ overexpression inhibit LPS-induced TNF-␣ expression and TNF-␣-downstream proapoptotic protein activation
NFB activation inhibitor (QNZ) and TNF-␣-converting enzyme (TACE) inhibitor (TAPI-0) suppressed the LPS-triggered signalling pathway, and completely inhibited LPS-activated caspase-3 in myocardial cells
Selective JNK1/2 inhibitor SP600125 inhibits LPS-induced IB␣ degradation and TNF-␣ expression in myocardial cells
We (Fig. 7A-C) . (Fig. 8) .
Fig. 3 E2, BSA-E2 and ER␣ overexpression inhibited LPS-induced TNF-␣ expression and TNF-␣-downstream pro-apoptotic protein activation. (A) TetOn/ER␣ H9c2 cells were cultured with TNF-␣ (0-5 ng/ml) for 24 hrs. Cells were harvested and detected by immunoblotting using a specific antibody against active caspase 3. Percentage of myocardial cell apoptosis by TNF-␣ (2 ng/ml) treatment was determined by the TUNEL assay. (B) Myocardial cells pre-incubated with 6-Amino-4-(4-phenoxyphenylethylamino) quinazoline (QNZ) and N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine Amide (TAPI-0) were treated with LPS (1 g/ml) for 24 hrs and harvested for immunoblotting analysis with a specific anti-active caspase-3 antibody. (C) After indicated treatments, cells were harvested and lysed for RT-PCR and immunoblotting analysis. RT-PCR was performed with the indicated primers of TNF-␣ and GAPDH. Immunoblotting was performed using a TNF-␣ antibody. Equal loading was assessed with an anti-␣-tubulin antibody. (D) Cells were incubated with or without E2 (10
the expression of TNF-␣ in myocardial cells that had been pretreated with SP600125 for 1 hr, followed by incubation with LPS for 3 or 15 hrs (Fig. 4C). The result suggests that JNK1/2 may mediate LPS-induced phosphorylation and degradation of IB␣, and the subsequent activation of NFB to modulate TNF-␣ expression in myocardial cells.
Activation of the PI3K-Akt pathway suppresses JNK1/2 activity, allowing for E 2 , BSA-E 2 and ER␣ to inhibit LPS-induced IB␣ degradation and nuclear localization of NFB
To examine whether E2 and/or ER␣ inhibit LPS-induced IB degradation and nuclear localization of NFB by suppressing JNK1/2 activity, we detected the level of activation/phosphorylation of JNK1/2 in Tet-On/ER␣ H9c2 myocardial cells that had been administrated E2 (10 Ϫ8 M), BSA-E2 (E2 ϭ 10 ng/ml) or Dox (1 /ml) in the presence of LPS (1 g/ml) for 30 min. We observed that JNK1/2 activity was significantly inhibited by E2, BSA-E2 and ER␣. However, the reduction in JNK1/2 activity was reversed by LY294002 (PI3K inhibitor) treatment (Fig. 5A-C). Several studies have shown that ␤-tranducin repeats containing protein (␤-TrCP) mediates ubiquitination/proteasome-dependent degradation of IB [14]; thus, we further examined the association between IB and ␤-TrCP in myocardial cells (Fig. 5D). The results of the immunoprecipitation assay showed that administrations of E2 (10
Ϫ8 M), Dox (1 g/ml), E2 (10 Ϫ8 M) plus Dox (1 g/ml) or BSA-E2 (E2 ϭ
ng/ml) inhibited the interaction between IB and ␤-TrCP proteins, compared with the LPS-treated group (lanes 3 and 4). However, LY294002 treatment suppressed the protective effects of E2 and ER␣, resulting in formation of the IB-␤-TrCP complex (Fig. 5D), degradation of IB␣ (Fig. 5E-G) and nuclear localization of NFB (Fig. 5H). These findings suggested that E2 and ER␣ inhibit LPS-induced IB␣ degradation and nuclear localization of NFB by suppressing JNK1/2 activity in the PI3K-Akt pathway.
PI3K SiRNA inhibits the cardioprotective effects of E 2 , ER␣ and BSA-E 2 in LPS-treated Tet-On/ER␣ H9c2 myocardial cells
To confirm whether Akt is involved in E2-and ER␣-mediated cardioprotective mechanisms, we applied small interfering RNA © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 Selective JNK inhibitor SP600125 blocked LPS-induced IB␣ degradation and TNF-␣ expression in myocardial cells. (A and B)
Discussion
In this study, we found that LPS directly induces myocardial cell apoptosis via the TNF-␣ death-receptor-dependent (TNF-␣, active
BSA-E2 and ER␣ by inhibiting LPS-induced TNF-␣ and active caspase-3 expression as well as apoptosis in myocardial cells
Evidence suggests that plasma concentrations of LPS are raised in patients with chronic heart failure (CHF) and an activated immune system [15] . LPS is a potent stimulator of proinflammatory cytokine (PIC) production in cardiomyocytes [16] . The elevation of circulating PICs, such as IL-1 [17] and IL-6 [18] , is associated with worsening of symptoms and even mortality [19] in patients with CHF. PICs have been shown to cause cardiac dysfunction by suppressing myocardial contractility [20] . In cardiomyocytes, TLR-4 specifically recognizes LPS [21] . Studies have suggested that TLR-4-mediated cytokine expression plays a 
HOS (E3, an ubiquitin ligase) is targeted for proteasomal degradation. After transcription and translation, trimeric TNF-␣ is inserted into the cell membrane. TNF-␣ converting enzyme (TACE) cleaves the pro-form of TNF-␣ off the cell membrane, which yields a soluble form of TNF-␣ (sTNF-␣) that then binds to TNF receptor-I (TNFR-I) through the autocrine loop to activate downstream caspases, thereby executing cardiomyocyte apoptosis. E2, acting through cytosolic ER␣ or membrane ER␣, and ER␣ overexpression alone inside the cells block LPS-induced JNK1/2 activation by activating the PI3K-Akt pathway. This blockade helps to maintain the association between IB and NFB and to inhibit nuclear localization of NFB, thereby inhibiting cardiomyocyte apoptosis.
role in immune-mediated progression of atherosclerosis [22] , in heart dysfunction during bacterial sepsis [23] and in myocardial ischaemia/reperfusion (I/R) damage [24] . Our [26, 27] . In a clinical study involving patients with sepsis, Schroder et al. reported that the mortality rate and the levels of TNF-␣ were lower in women than in men [11] . After burn trauma injury, women tend to have lower levels of cytokine production, lower myocardial inflammatory responses and better myocardial function [28] . Deshpande et al. showed that estradiol inhibited LPSinduced NFB-binding activity and TNF-␣ expression in macrophages in an animal model [29] . In addition, the cardiovascular protective effects of estrogen administration in vivo have been shown in a left anterior descending (LAD) coronary artery ischaemia/reperfusion model [30] , in a coronary artery occlusion model [12] and in an abdominal aorta coarctation model [13] 
